Pneumococcal and Influenza Vaccination in Bronchiectasis
All patients with bronchiectasis should receive both pneumococcal conjugate vaccine (PCV20 or PCV21) and annual inactivated influenza vaccine, as bronchiectasis is a chronic suppurative lung disease that places patients at high risk for severe respiratory infections and exacerbations.
Pneumococcal Vaccination Regimen
For adults with bronchiectasis aged ≥50 years who have never received pneumococcal vaccine, administer a single dose of PCV20 or PCV21 1. This recommendation is based on the 2024 ACIP expanded guidelines that now include all adults ≥50 years, and bronchiectasis patients qualify due to their chronic lung disease status.
For adults aged 19-49 years with bronchiectasis, the same single-dose PCV20 or PCV21 recommendation applies, as they have a risk condition for pneumococcal disease 1.
Evidence Supporting Pneumococcal Vaccination
Limited but supportive evidence exists for pneumococcal vaccination in bronchiectasis. One randomized controlled trial in 167 adults with chronic lung disease (including bronchiectasis) demonstrated that 23-valent pneumococcal vaccine combined with influenza vaccine significantly reduced acute infective respiratory exacerbations compared to influenza vaccine alone (OR=0.48,95%CI 0.26-0.88; NNT=6 over 2 years) 2. While this study used the older PPSV23 formulation, it provides the strongest clinical evidence for benefit in this population.
The newer conjugate vaccines (PCV20/PCV21) are now preferred over the older PPSV23 due to superior immunogenicity and the elimination of need for booster doses 1.
Recent real-world data from 3,066 patients with chronic airway diseases (including bronchiectasis) hospitalized for influenza showed that completed pneumococcal vaccination provided significant protection against secondary bacterial pneumonia (adjusted OR=0.74), all-cause mortality (adjusted OR=0.12), and respiratory mortality (adjusted OR=0.04) 3. This demonstrates meaningful clinical benefit beyond just preventing pneumococcal disease.
Influenza Vaccination Regimen
Administer annual inactivated influenza vaccine (standard or high-dose formulations) to all patients with bronchiectasis 4, 5. While no randomized controlled trials specifically examine influenza vaccine efficacy in bronchiectasis patients, the recommendation is based on:
- Universal guidelines for patients with chronic pulmonary diseases 4
- The demonstrated synergistic benefit when combined with pneumococcal vaccination 2, 3
- The high risk of severe outcomes from influenza in patients with underlying lung disease
Coadministration Strategy
Both vaccines can be safely administered during the same visit 6. A 2023 phase 3 trial in 1,796 adults ≥65 years demonstrated that coadministration of PCV20 with quadrivalent influenza vaccine was noninferior to separate administration for both pneumococcal and influenza antibody responses 6. The only notable difference was slightly increased mild-to-moderate fatigue with coadministration (20.0% vs 10.8-12.6% for mild fatigue), which was not clinically significant 6.
Alternatively, vaccines can be given 28 days apart if preferred, though this may reduce patient compliance 7.
Key Clinical Considerations
Common Pitfalls to Avoid:
- Do not use PPSV23 as initial vaccination in the current era—PCV20 or PCV21 are superior first-line options 1
- Do not delay vaccination waiting for a "stable" period—the goal is prevention of exacerbations
- Do not use live attenuated influenza vaccine (nasal spray)—only inactivated formulations are appropriate for patients with chronic lung disease 5
Important Caveats:
- The evidence base specifically for bronchiectasis is limited, with only one small RCT and observational data 2, 4, 8
- No data exists on optimal revaccination intervals for pneumococcal vaccines in bronchiectasis—current single-dose recommendations should be followed 2, 1
- Influenza vaccination must be repeated annually, ideally before flu season begins
For Immunosuppressed Bronchiectasis Patients:
If patients are on immunosuppressive therapy, pneumococcal and inactivated influenza vaccines remain strongly recommended 5. However, vaccine efficacy may be reduced, and timing relative to immunosuppressive therapy should be optimized when possible (ideally before initiation or during periods of lower immunosuppression).